INDEMNIFICATION AGREEMENTIndemnification Agreement • June 25th, 2014 • Proteon Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is; made and entered into as of March 29, 2006 between PROTEON THERAPEUTICS, INC., Delaware corporation (the “Company”), and Brendan O’Leary (“Indemnitee”),
PROTEON THERAPEUTICS, INC. STOCK OPTION AGREEMENT (INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION)Stock Option Agreement • June 25th, 2014 • Proteon Therapeutics Inc • Biological products, (no disgnostic substances)
Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Stock Option Agreement, PROTEON THERAPEUTICS, INC. (the “Company”) has granted you an option under its 2006 EQUITY INCENTIVE PLAN (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. Defined terms not explicitly defined in this Stock Option Agreement but defined in the Plan shall have the same definitions as in the Plan.
Process Development and Manufacturing Services Agreement by and between Proteon Therapeutics and Lonza LtdServices Agreement • June 25th, 2014 • Proteon Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This Process Development and Manufacturing Services Agreement (this “Agreement”) is effective as of September 1, 2009 (the “Effective Date”), by and between Proteon Therapeutics, a Delaware corporation, with an address at 200 West Street, Waltham, Massachusetts (“PROTEON”), and Lonza Ltd, a Swiss company with an address at Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland (“LONZA”) (each, a “Party” and together the “Parties”).
ASSIGNMENT OF RIGHTS/LICENSE AGREEMENT NIH Sponsored InventionAssignment of Rights • June 25th, 2014 • Proteon Therapeutics Inc • Biological products, (no disgnostic substances)
This Agreement, effective this 4th day of February 2002, is between the Johns Hopkins University, a corporation of the State of Maryland, having a principle place of business at 720 Rutland Avenue, Baltimore, Maryland 21205 (hereinafter referred to as “JHU”) and F. Nicholas Franano, an individual, residing at 1010 W. 69th Terrace, Kansas City, MO 64113 (hereinafter referred to as “FRANANO”).
ASSIGNMENT OF PATENTAssignment of Patent • June 25th, 2014 • Proteon Therapeutics Inc • Biological products, (no disgnostic substances)
This Assignment, made and entered into on this 30th day of December, 2002 by and between F. Nicholas Franano, an individual residing in Kansas City, Missouri (“Assignor”), and Proteon Therapeutics, L.L.C., a Missouri Limited Liability Company (“Assignee”).
